Considering the involvement of SLC22A17 in iron trafficking, the dysregulation of SLC22A17 plays a key role in the development, progression, and drug resistance of several tumors, including cutaneous melanoma (CM) [29–32]. This evidence concerns the gene SLC22A17 and cutaneous mastocytosis.